ATE336252T1 - Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie - Google Patents

Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie

Info

Publication number
ATE336252T1
ATE336252T1 AT03716467T AT03716467T ATE336252T1 AT E336252 T1 ATE336252 T1 AT E336252T1 AT 03716467 T AT03716467 T AT 03716467T AT 03716467 T AT03716467 T AT 03716467T AT E336252 T1 ATE336252 T1 AT E336252T1
Authority
AT
Austria
Prior art keywords
sulfatase
continuous
amount
substitution therapy
containing hormone
Prior art date
Application number
AT03716467T
Other languages
English (en)
Inventor
Patrick Michel Caubel
Andrew Joseph Friedmen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE336252T1 publication Critical patent/ATE336252T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT03716467T 2002-03-11 2003-03-11 Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie ATE336252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36314802P 2002-03-11 2002-03-11
US38154102P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
ATE336252T1 true ATE336252T1 (de) 2006-09-15

Family

ID=28045285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03716467T ATE336252T1 (de) 2002-03-11 2003-03-11 Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie

Country Status (13)

Country Link
US (1) US20030229057A1 (de)
EP (1) EP1482948B1 (de)
JP (1) JP2005519961A (de)
CN (1) CN1652798A (de)
AT (1) ATE336252T1 (de)
AU (1) AU2003220171A1 (de)
CA (1) CA2478194A1 (de)
CY (1) CY1105646T1 (de)
DE (1) DE60307602T2 (de)
DK (1) DK1482948T3 (de)
ES (1) ES2269999T3 (de)
PT (1) PT1482948E (de)
WO (1) WO2003077924A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
RU2351339C2 (ru) * 2001-12-05 2009-04-10 Дюрамед Фармасьютикалс, Инк. Оральные контрацептивы для предотвращения беременности и уменьшения предменструальной симптоматики
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US7576226B2 (en) 2003-06-30 2009-08-18 Richter Gedeon Vegyeszeti Gyar Rt. Process of making isomers of norelgestromin and methods using the same
AU2004257772B2 (en) * 2003-07-16 2009-12-17 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US7556150B2 (en) * 2004-06-07 2009-07-07 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of DUB
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070077269A1 (en) * 2005-10-04 2007-04-05 Woodward John R Method of birth control and hormone regulation
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545397A (en) * 1969-03-17 1970-12-08 Dowty Technical Dev Ltd Air-cushion vehicles and like craft
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4292965A (en) * 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
EP0559240B1 (de) * 1987-09-24 2001-12-05 Jencap Research Limited Oestrogen und Progestin enthaltende Verhütungspackungen
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5252334A (en) * 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
HU228434B1 (en) * 1995-06-07 2013-03-28 Ortho Mcneil Pharm Inc Transdermal medicament for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
PT1611892E (pt) * 2000-01-18 2009-11-20 Bayer Schering Pharma Ag Composições farmacêuticas compreendendo drospirenona

Also Published As

Publication number Publication date
US20030229057A1 (en) 2003-12-11
EP1482948A1 (de) 2004-12-08
AU2003220171A1 (en) 2003-09-29
DE60307602T2 (de) 2007-10-04
HK1070003A1 (en) 2005-06-10
ES2269999T3 (es) 2007-04-01
DK1482948T3 (da) 2006-11-27
EP1482948B1 (de) 2006-08-16
DE60307602D1 (de) 2006-09-28
WO2003077924A1 (en) 2003-09-25
PT1482948E (pt) 2006-11-30
CN1652798A (zh) 2005-08-10
CA2478194A1 (en) 2003-09-25
CY1105646T1 (el) 2010-12-22
JP2005519961A (ja) 2005-07-07

Similar Documents

Publication Publication Date Title
ATE336252T1 (de) Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
HRP20020837B1 (hr) Liječenje nadoknadom hormona
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
GB0001309D0 (en) Valve arrangement
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
TR200101120T2 (tr) Serin proteaz inhibitörü
BG106104A (en) Method for the treatment of diseases related to increased number of neutrophils or neutrophil overactivation
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
GB0020504D0 (en) Therapeutic method
TW200626161A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
MXPA02009744A (es) Uso de fulvestrant en el tratamiento de cancer resistente de mama.
BR0311146A (pt) Uso de tibolona e de modulador de receptor de estrogênio seletivo, e, método e kit para o tratamento de um sintoma relacionado com a deficiência de estrogênio em um paciente do sexo feminino
ATE198707T1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
MY140723A (en) Method of treatment
SE9902597D0 (sv) New use
MY136880A (en) Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
MXPA05009656A (es) Regimenes contraceptivos transdermicos extendidos.
Bygdeman et al. Medical termination of early pregnancy: the Swedish experience
RO118794B1 (ro) Metodă de tratament a unor stări dependente de steroizii gonadici
DE60202954D1 (de) Tetrahydrochinolin-derivate zur behandlung von krankheiten ausgelöst durch zu hohem oder zu niedrigem oestrogenspiegel
EP1025098A4 (de) Bentzothiophene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1482948

Country of ref document: EP